Global Viral Vectors & Plasmid DNA Market Report 2020-2023 & 2030 with Focus on COVID-19 Implications and Growth

DUBLIN, Jan. 12, 2021 /PRNewswire/ -- The "Viral Vectors & Plasmid DNA Global Market Report 2020-30: COVID-19 Implications and Growth" report has been added to ResearchAndMarkets.com's offering.

Viral Vectors & Plasmid DNA Global Market Report 2020-30: COVID-19 Implications and Growth provides the strategists, marketers and senior management with the critical information they need to assess the global viral vectors & plasmid dna market.

Major players in the viral vectors & plasmid DNA market are FUJIFILM Diosynth Biotechnologies, FinVector Vision Therapies, Lonza, Cobra Biologics and Pharmaceutical Services, Brammer Bio, Cell and Gene Therapy Catapult, VGXI, and MassBiologics.

The global viral vectors & plasmid DNA market is expected to grow from $0.46 billion in 2019 to $0.60 billion in 2020 at a compound annual growth rate (CAGR) of 31.3%. The growth is mainly due to the outbreak of COVID 19 and requires targeted delivery of the drug to treat affected patients. The number of cases has been increasing resulting in a surge in demand for viral vectors & plasmid DNA. The market is expected to reach $1.05 billion in 2023 at a CAGR of 20.4%.

The viral vectors & plasmid DNA market consists of sales of viral vectors & plasmid DNA and related services. The viral vectors & plasmid DNA are used for the delivery of cellular therapies, like gene therapy and immunotherapy, and also for treating some viral infections. The viral vectors & plasmid DNA are used for formulation development in research and development labs. The viral vectors are genetically engineered viruses carrying viral RNA or DNA that is noninfectious but still contain viral promoters and transgene. The plasmid DNA is a double-stranded extrachromosomal and circular DNA sequence that is capable of replication using the host cell's replication system.

North America was the largest region in the viral vectors and plasmid DNA market in 2019. Asia Pacific is expected to be the fastest-growing region in the forecast period.

In January 2020, Cognate Bioservices Inc, a US-based company skilled in cell and cell-mediated gene therapy products, acquired Cobra Biologics, specialized in providing manufacturing services for plasmid DNA and viral vector, for an undisclosed amount. The acquisition is expected to create a platform for the life cycle management of cell and gene therapy products. Cobra biologics is well established in the development and manufacture of a variety of viral vectors and DNA. The combined Cognate and Cobra expertise is expected to push both the businesses to a better position to respond to current and future market demand.

The viral vectors & plasmid DNA market covered in this report is segmented by product into plasmid DNA; viral vectors and by applications into gene and cancer therapies; viral infections; immunotherapy; formulation development; others.

The unaffordable cost of gene therapies is a major challenge in the viral vectors & plasmid DNA market. The prices of gene therapies range between $0.2 million to $2.1 million. For instance, Gilead company's Yescarta is a gene therapy that costs around $0.3 million and Bluebird Bio's Letiglobin is another gene therapy costing around $2.1 million. The high price is due to various factors like government regulations, production costs, and so on. Therefore, the unaffordable cost of gene therapies is limiting the viral vector & plasmid DNA market growth.

The rise in the global incidence of cancer is driving the viral vector & plasmid DNA market. According to Cancer Research UK, in 2018, around 17 million new cases of cancer were recorded with deaths of around 9.6 million, and the estimated cancer incidence rate is 62% between 2018-2040 worldwide. The rise in the global incidence of cancer has boosted the demand for the viral vectors and plasmid DNA market.

Key Topics Covered:

1. Executive Summary

2. Viral Vectors & Plasmid DNA Market Characteristics

3. Viral Vectors & Plasmid DNA Market Size and Growth

3.1. Global Viral Vectors & Plasmid DNA Historic Market, 2015 - 2019, $ Billion

3.1.1. Drivers of the Market

3.1.2. Restraints on the Market

3.2. Global Viral Vectors & Plasmid DNA Forecast Market, 2019 - 2023F, 2025F, 2030F, $ Billion

3.2.1. Drivers of the Market

3.2.2. Restraints on the Market

4. Viral Vectors & Plasmid DNA Market Segmentation

4.1. Global Viral Vectors & Plasmid DNA Market, Segmentation by Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

• Plasmid DNA
• Viral vectors

4.2. Global Viral Vectors & Plasmid DNA Market, Segmentation by Applications, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

• Gene and Cancer Therapies
• Viral Infections
• Immunotherapy
• Formulation Development
• Others

5. Viral Vectors & Plasmid DNA Market Regional and Country Analysis

5.1. Global Viral Vectors & Plasmid DNA Market, Split by Region, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

5.2. Global Viral Vectors & Plasmid DNA Market, Split by Country, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

Companies Mentioned

• FUJIFILM Diosynth Biotechnologies
• FinVector Vision Therapies
• Lonza
• Cobra Biologics and Pharmaceutical Services
• Brammer Bio
• Cell and Gene Therapy Catapult
• VGXI
• MassBiologics
• Sanofi
• Spark Therapeutics
• UniQure
• Thermo Fisher Scientific
• VIROVEK
• SIRION Biotech GmbH
• ALDEVRON
• Oxford BioMedica
• Plasmid Factory
• Biovian
• BioReliance
• 4D Molecular Therapeutics
• Renova Therapeutics
• Shenzhen SiBiono GeneTech Co.
• Vigene Biosciences Inc.
• Novasep
• Genzyme Corporation
• Oxford Gene Technology
• Richter-Helm
• MolMed

For more information about this report visit https://www.researchandmarkets.com/r/m2vrrw

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

Related Links

http://www.researchandmarkets.com